AstraZeneca two-in-one drug succeeds in lung disease test

Reuters LONDON | Updated on January 24, 2018 Published on March 18, 2015

AstraZeneca said on Wednesday its experimental lung drug PT003 for chronic lung disease had proved successful in two final-stage Phase III trials, boosting hopes for the company's respiratory pipeline.

The drug, which AstraZeneca acquired after buying Pearl Therapeutics two years ago, combines a long-acting beta-2 agonist (LABA) and a long-acting muscarine antagonist (LAMA). AstraZeneca plans to file PT003 for approval commencing in 2015.

Rival firms also have LAMA/LABA drugs that are more advanced than PT003, but AstraZeneca's drug is administered with a pressurised meter-dose inhaler instead of a dry-powder inhaler, which may suit elderly patients in particular.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on March 18, 2015
This article is closed for comments.
Please Email the Editor